Allergan’s Net Revenues Increase 2.8 Percent; Restasis Sales Drop 17.2 Percent

May 4, 2018: By Jon Swedien

Allergan’s Q1-2018 net revenues were $3.67 billion, a 2.8 percent increase from the same quarter in 2017, the Dublin-based company announced April 30.

US net revenues for Restasis in Q1-2018 were $255.8 million, a 17.2 percent decrease compared with the dry eye drug’s net revenues from Q1-2017. Allergan said demand growth for Restasis of 4 percent was offset by trade buying patterns and lower net selling prices.

US net revenues for Ozurdex (dexamethasone intravitreal implant), for diabetic macular edema, were $25.5 million, a 13.3 percent increase compared with Q1-2017.

Allergan reported May 3 that its board declared a cash dividend of $0.72 per ordinary share for Q2-2018. The dividend will be paid June 15 to shareholders of record at the close of business May 18, the company said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility